Ultromics Secures €48M Series C for AI Heart Diagnostics

Oxford-based Ultromics, an innovator in AI-driven cardiology diagnostics, secured €48 million in its Series C funding round. L&G, Allegis Capital, and Lightrock co-led the investment. This capital will accelerate the company's expansion.

The funding round also received continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Additionally, University of Chicago Medicine and UPMC Enterprises participated. Ultromics develops AI heart diagnostics solutions.

Ultromics' EchoGo platform detects elusive forms of heart failure. It uses AI to analyze routine echocardiograms.

Advancing AI Heart Diagnostics

Founded in 2017, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology for Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis. Conventional solutions often miss or delay these diagnoses. Consequently, Ultromics addresses this diagnostic gap.

The company will use the proceeds to expand across the US and other key markets. Furthermore, Ultromics plans to broaden its product pipeline to include additional cardiac conditions. This expansion also covers new distribution channels and deeper partnerships with health systems.

Ultromics has analyzed over 430,000 echocardiograms. In clinical studies, EchoGo improved HFpEF detection by 73.6%. Its latest diagnostic model for cardiac amyloidosis outperformed current clinical risk scores. This demonstrates the platform's effectiveness in medical diagnostics.

The platform assists hospitals by reducing unnecessary tests and streamlining workflows. It enables earlier treatment initiation. This approach enhances medical interventions while reducing costs, similar to advancements seen with companies like HeartFlow in cardiac imaging.

Ultromics received FDA Breakthrough Device clearance for EchoGo Amyloidosis in late 2024. Subsequently, it launched EchoGo Score in 2025. This new feature adds AI-driven probability scoring to EchoGo Heart Failure, enhancing detection nuance for cardiovascular disease.

Growing adoption and partnerships include University of Chicago Medicine, University Hospitals Cleveland, Northwestern University, and Mayo Clinic. Ultromics builds regional clinical and commercial traction, particularly in high-prevalence regions.